On January 6, 2026, Crinetics Pharmaceuticals, a pharmaceutical company focused on the discovery, development, and commercialization of novel therapeutics for endocrine diseases and endocrine-related tumors, announced the pricing of an underwritten public offering of 7,620,000 shares of its common stock at a price to the public of $45.95 per share. All of the shares to be sold in the offering are to be sold by Crinetics, and the gross proceeds from the offering, before deducting the underwriting discounts and commissions and other offering expenses, are expected to be approximately $350 million. Wilson Sonsini Goodrich & Rosati advised Crinetics on patent matters related to the public offering.

Additionally, Crinetics has granted the underwriters a 30-day option to purchase up to an additional 1,143,000 shares of common stock. Crinetics intends to use the net proceeds from the offering, together with its cash, cash equivalents, and investment securities, to fund its commercial activities in connection with the launch of PALSONIFY™, research and development of its product candidates, other research programs, and other general corporate purposes.

The Wilson Sonsini team that advised Crinetics on patent matters included Uale Taotafa, Tyler Baguley, Val Zunic, and Mike Hostetler.

For more information, please see Crinetics’ news release.